A citation-based method for searching scientific literature

Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E Kadel, Hartmut Koeppen, Jillian L Astarita, Rafael Cubas, Suchit Jhunjhunwala, Romain Banchereau, Yagai Yang, Yinghui Guan, Cecile Chalouni, James Ziai, Yasin Şenbabaoğlu, Stephen Santoro, Daniel Sheinson, Jeffrey Hung, Jennifer M Giltnane, Andrew A Pierce, Kathryn Mesh, Steve Lianoglou, Johannes Riegler, Richard A D Carano, Pontus Eriksson, Mattias Höglund, Loan Somarriba, Daniel L Halligan, Michiel S van der Heijden, Yohann Loriot, Jonathan E Rosenberg, Lawrence Fong, Ira Mellman, Daniel S Chen, Marjorie Green, Christina Derleth, Gregg D Fine, Priti S Hegde, Richard Bourgon, Thomas Powles. Nature 2018
Times Cited: 1153







List of co-cited articles
1093 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
Daniele V F Tauriello, Sergio Palomo-Ponce, Diana Stork, Antonio Berenguer-Llergo, Jordi Badia-Ramentol, Mar Iglesias, Marta Sevillano, Sales Ibiza, Adrià Cañellas, Xavier Hernando-Momblona,[...]. Nature 2018
648
30

Transforming Growth Factor-β Signaling in Immunity and Cancer.
Eduard Batlle, Joan Massagué. Immunity 2019
416
15

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
15

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
15

The Immune Landscape of Cancer.
Vésteinn Thorsson, David L Gibbs, Scott D Brown, Denise Wolf, Dante S Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, Galen F Gao, Christopher L Plaisier, James A Eddy,[...]. Immunity 2018
13

Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick,[...]. Nat Med 2018
12

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
11

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Rikke B Holmgaard, David A Schaer, Yanxia Li, Stephen P Castaneda, Mary Y Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R Manro, Philip W Iversen,[...]. J Immunother Cancer 2018
133
11

clusterProfiler: an R package for comparing biological themes among gene clusters.
Guangchuang Yu, Li-Gen Wang, Yanyan Han, Qing-Yu He. OMICS 2012
10

GSVA: gene set variation analysis for microarray and RNA-seq data.
Sonja Hänzelmann, Robert Castelo, Justin Guinney. BMC Bioinformatics 2013
10

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Julius Strauss, Christopher R Heery, Jeffrey Schlom, Ravi A Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L Marté, Renee N Donahue, Italia Grenga,[...]. Clin Cancer Res 2018
154
10


Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.
Alexandre Calon, Enza Lonardo, Antonio Berenguer-Llergo, Elisa Espinet, Xavier Hernando-Momblona, Mar Iglesias, Marta Sevillano, Sergio Palomo-Ponce, Daniele V F Tauriello, Daniel Byrom,[...]. Nat Genet 2015
557
10

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
942
10

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
10

Robust enumeration of cell subsets from tissue expression profiles.
Aaron M Newman, Chih Long Liu, Michael R Green, Andrew J Gentles, Weiguo Feng, Yue Xu, Chuong D Hoang, Maximilian Diehn, Ash A Alizadeh. Nat Methods 2015
9

limma powers differential expression analyses for RNA-sequencing and microarray studies.
Matthew E Ritchie, Belinda Phipson, Di Wu, Yifang Hu, Charity W Law, Wei Shi, Gordon K Smyth. Nucleic Acids Res 2015
9

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski. Nature 2015
9

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M Hernández,[...]. Sci Transl Med 2018
178
9

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, Thomas Powles, Daniel P Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia,[...]. Lancet 2017
960
9


Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, Catherine J Wu, Gad Getz, Nir Hacohen. Cell 2015
8

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Diana Miao, Claire A Margolis, Wenhua Gao, Martin H Voss, Wei Li, Dylan J Martini, Craig Norton, Dominick Bossé, Stephanie M Wankowicz, Dana Cullen,[...]. Science 2018
434
8

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly,[...]. N Engl J Med 2016
8

Microenvironmental regulation of tumor progression and metastasis.
Daniela F Quail, Johanna A Joyce. Nat Med 2013
8

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
8


A framework for advancing our understanding of cancer-associated fibroblasts.
Erik Sahai, Igor Astsaturov, Edna Cukierman, David G DeNardo, Mikala Egeblad, Ronald M Evans, Douglas Fearon, Florian R Greten, Sunil R Hingorani, Tony Hunter,[...]. Nat Rev Cancer 2020
427
8

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
A Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D Cherniack, Toshinori Hinoue, Peter W Laird, Katherine A Hoadley, Rehan Akbani,[...]. Cell 2017
786
8

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda,[...]. Lancet Oncol 2017
784
8

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
619
8

Inferring tumour purity and stromal and immune cell admixture from expression data.
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-Garcia, Victor Treviño, Hui Shen, Peter W Laird, Douglas A Levine,[...]. Nat Commun 2013
7

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
7

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
7

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova, Clemens Mayer, Mirjana Efremova, Dietmar Rieder, Hubert Hackl, Zlatko Trajanoski. Cell Rep 2017
694
7

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
921
7

Contextual determinants of TGFβ action in development, immunity and cancer.
Charles J David, Joan Massagué. Nat Rev Mol Cell Biol 2018
241
7

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nisha Nagarsheth, Max S Wicha, Weiping Zou. Nat Rev Immunol 2017
623
7

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig, James O Jones, Matthew Kraman, Richard J B Wells, Andrew Deonarine, Derek S Chan, Claire M Connell, Edward W Roberts, Qi Zhao, Otavia L Caballero,[...]. Proc Natl Acad Sci U S A 2013
847
7

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, Chengwen Liu, Shruti Malu, Caitlin Creasy, Michael T Tetzlaff, Chunyu Xu, Jodi A McKenzie, Chunlei Zhang, Xiaoxuan Liang,[...]. Cancer Discov 2016
692
7

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
7

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri,[...]. N Engl J Med 2017
7

The consensus molecular subtypes of colorectal cancer.
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino,[...]. Nat Med 2015
7

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, Gottfrid Sjödahl, A Gordon Robertson, Roland Seiler, Katherine A Hoadley, Clarice S Groeneveld, Hikmat Al-Ahmadie, Woonyoung Choi,[...]. Eur Urol 2020
188
7

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Woonyoung Choi, Sima Porten, Seungchan Kim, Daniel Willis, Elizabeth R Plimack, Jean Hoffman-Censits, Beat Roth, Tiewei Cheng, Mai Tran, I-Ling Lee,[...]. Cancer Cell 2014
864
7

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
7

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles, Ignacio Durán, Michiel S van der Heijden, Yohann Loriot, Nicholas J Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta M Retz, Daniel Castellano, Aristotelis Bamias,[...]. Lancet 2018
603
7

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Matthew D Galsky, José Ángel Arranz Arija, Aristotelis Bamias, Ian D Davis, Maria De Santis, Eiji Kikuchi, Xavier Garcia-Del-Muro, Ugo De Giorgi, Marina Mencinger, Kouji Izumi,[...]. Lancet 2020
139
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.